Droplet digital pcr for oncogenic kmt2a fusion detection
Acute myeloid leukemia (AML) is an aggressive blood cancer diagnosed in ∼120,000 individuals worldwide each year. During treatment for AML, detecting residual disease is essential for prognostication and treatment decision-making. Currently, methods for detecting residual AML are limited to identifying ∼1:100-1:1,000 leukemic cells (morphology, DNA sequencing) or di fficult to implement (flow cytometry). AML arising after chemotherapy or radiation exposure is termed therapy-related AML (t-AML) and is exceptionally aggressive and treatment resistant.
Source: Journal of Molecular Diagnostics - Category: Pathology Authors: Andrew L. Young, Hannah C. Davis, Grant A. Challen Tags: Technical Advance Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Chemotherapy | Grants | Information Technology | Leukemia | Pathology